Page 137 - 《中国药房》2025年1期

患者亚群（如CYP3A5*1/*1、CYP3A5*1/*3、CYP3A5*3/*3 Br J Clin Pharmacol，2014，77（6）：1051-1063.
[40]
基因型） ——由于药物代谢基因的分型不同，上述亚 [11] WANG D D，CHEN X，LI Z P. Wuzhi capsule and haemo‐
群在相同他克莫司治疗剂量下有不同的药物反应，而 globin influence tacrolimus elimination in paediatric kid‐
ML结合PPK模型有助于识别不同亚群的患者并对其进 ney transplantation patients in a population pharmacoki‐
netics analysis：a retrospective study[J]. J Clin Pharm
行精准治疗，同时准确预测他克莫司的清除率，优化给
Ther，2019，44（4）：611-617.
药剂量。综上所述，结合儿童发育药理学特点的多种建
[12] CHEN X，WANG D D，XU H，et al. Population pharmaco‐
模方法的综合运用可能成为未来研究的趋势，从而为儿
kinetics and pharmacogenomics of tacrolimus in Chinese
童他克莫司的个体化精准治疗提供有力支持。
children receiving a liver transplant：initial dose recom‐
参考文献 mendation[J]. Transl Pediatr，2020，9（5）：576-586.
[ 1 ] THOMSON A W，BONHAM C A，ZEEVI A. Mode of ac‐ [13] CHEN X，WANG D D，XU H，et al. Population pharmaco‐
tion of tacrolimus （FK506）：molecular and cellular kinetics model and initial dose optimization of tacrolimus
mechanisms[J]. Ther Drug Monit，1995，17（6）：584-591. in children and adolescents with lupus nephritis based on
[ 2 ] BRUNET M，VAN GELDER T，ÅSBERG A，et al. Thera‐ real-world data[J]. Exp Ther Med，2020，20（2）：1423-
peutic drug monitoring of tacrolimus-personalized 1430.
therapy：second consensus report[J]. Ther Drug Monit， [14] LEONG R，VIEIRA M L，ZHAO P，et al. Regulatory
2019，41（3）：261-307. experience with physiologically based pharmacokinetic
[ 3 ] MENDOZA ROJAS A，HESSELINK D A，VAN BESOUW modeling for pediatric drug trials[J]. Clin Pharmacol
N M，et al. High tacrolimus intrapatient variability and Ther，2012，91（5）：926-931.
subtherapeutic immunosuppression are associated with [15] EDGINTON A N，SCHMITT W，WILLMANN S. Deve-
adverse kidney transplant outcomes[J]. Ther Drug Monit， lopment and evaluation of a generic physiologically based
2022，44（3）：369-376. pharmacokinetic model for children[J]. Clin Pharmacoki‐
[ 4 ] FUNK R S，BROWN J T，ABDEL-RAHMAN S M. Pedia- net，2006，45（10）：1013-1034.
tric pharmacokinetics：human development and drug dis‐ [16] KUEPFER L，NIEDERALT C，WENDL T，et al. Applied
position[J]. Pediatr Clin North Am，2012，59（5）：1001- concepts in PBPK modeling：how to build a PBPK/PD
1016. model[J]. CPT Pharmacometrics Syst Pharmacol，2016，5
[ 5 ] KEARNS G L，ABDEL-RAHMAN S M，ALANDER S W， （10）：516-531.
et al. Developmental pharmacology：drug disposition， [17] LIN W，CHEN Y，UNADKAT J D，et al. Applications，
action，and therapy in infants and children[J]. N Engl J challenges，and outlook for PBPK modeling and simula‐
Med，2003，349（12）：1157-1167. tion：a regulatory，industrial and academic perspective[J].
[ 6 ] IWASAKI K. Metabolism of tacrolimus （FK506） and re‐ Pharm Res，2022，39（8）：1701-1731.
cent topics in clinical pharmacokinetics[J]. Drug Metab [18] TALHA ZAHID M，ZAMIR A，MAJEED A，et al. A
Pharmacokinet，2007，22（5）：328-335. physiologically based pharmacokinetic model of cefepime
[ 7 ] MIN S，PAPAZ T，LAFRENIERE-ROULA M，et al. A to predict its pharmacokinetics in healthy，pediatric and
randomized clinical trial of age and genotype-guided ta‐ disease populations[J]. Saudi Pharm J，2023，31（8）：
crolimus dosing after pediatric solid organ transplantation 101675.
[J]. Pediatr Transplant，2018，22（7）：e13285. [19] PRADO-VELASCO M，BOROBIA A，CARCAS-SANSUAN
[ 8 ] PRYTUŁA A A，CRANSBERG K，BOUTS A H，et al. A. Predictive engines based on pharmacokinetics model‐
The effect of weight and CYP3A5 genotype on the popula‐ ling for tacrolimus personalized dosage in paediatric renal
tion pharmacokinetics of tacrolimus in stable paediatric re‐ transplant patients[J]. Sci Rep，2020，10（1）：7542.
nal transplant recipients[J]. Clin Pharmacokinet，2016，55 [20] CAI L M，KE M，WANG H，et al. Physiologically based
（9）：1129-1143. pharmacokinetic model combined with reverse dose
[ 9 ] KHAMLEK K，KOMENKUL V，SRIBOONRUANG T， method to study the nephrotoxic tolerance dose of tacroli‐
et al. Population pharmacokinetic models of tacrolimus in mus[J]. Arch Toxicol，2023，97（10）：2659-2673.
paediatric solid organ transplant recipients：a systematic [21] HANKE，FRECHEN S，MOJ D，et al. PBPK models for
review[J]. Br J Clin Pharmacol，2024，90（2）：406-426. CYP3A4 and P-gp DDI prediction：a modeling network of
[10] KASSIR N，LABBÉ L，DELALOYE J R，et al. Popula‐ rifampicin，itraconazole，clarithromycin，midazolam，al‐
tion pharmacokinetics and Bayesian estimation of tacroli‐ fentanil，and digoxin[J]. CPT Pharmacometrics Syst Phar‐
mus exposure in paediatric liver transplant recipients[J]. macol，2018，7（10）：647-659.

中国药房 2025年第36卷第1期 China Pharmacy 2025 Vol. 36 No. 1 · 127 ·